Tirzepatide (Mounjaro/Zepbound) in New York: Providers and Price Guidance
National editorial estimate for tirzepatide (mounjaro/zepbound): $400–$1,500 per month. We do not have enough approved patient price reports to publish a New York sample median. This national range is general planning guidance, not a state average or provider quote. Request itemized quotes from New York providers.
Directory snapshot generated
By Sarah, Aesthetics Editor, Medical Spa Locator · Reviewed by Anna M. Melamed, MD · Data last checked
National editorial estimate
$400–$1,500 per month
Listed providers
17
Tirzepatide (Mounjaro/Zepbound) Providers by New York City
Explore tirzepatide (mounjaro/zepbound) providers in the New York cities with the most listed clinics on this page. Counts are directory coverage, not city price comparisons.
Tirzepatide (Mounjaro/Zepbound) in New York: Price Guidance FAQ
How much does tirzepatide (mounjaro/zepbound) cost in New York?+
National editorial estimate for tirzepatide (mounjaro/zepbound): $400–$1,500 per month. We do not have enough approved patient price reports to publish a New York sample median. This national range is general planning guidance, not a state average or provider quote. Request itemized quotes from New York providers.
How many tirzepatide (mounjaro/zepbound) providers are in New York?+
Medical Spa Locator lists 17 med spas offering tirzepatide (mounjaro/zepbound) in New York, averaging 5.0 stars on Google. Compare them by rating and review count, then confirm credentials directly.
How should I compare tirzepatide (mounjaro/zepbound) quotes in New York?+
Ask each provider to itemize the product or device, dose or treatment area, number of sessions, and any consultation or follow-up fees. Compare the same scope of treatment; directory counts and ratings do not establish local prices.
How is tirzepatide different from semaglutide?+
Tirzepatide targets two receptors (GIP and GLP-1) compared to one for semaglutide, often resulting in greater weight loss.
How much weight can I lose?+
In the FDA label's 72-week Zepbound study of adults without diabetes, mean body-weight change ranged from -15.0% at 5 mg to -20.9% at 15 mg, versus -3.1% with placebo; all groups received diet and activity intervention. Individual outcomes vary.